Nasdaq

BridgeBio Pharma’s Affiliate QED Therapeutics and Helsinn Group Announce Strategic Collaboration to Co-Develop and Commercialize Infigratinib in Oncology

- BridgeBio, through its affiliate QED (“BridgeBio”), and Helsinn to co-commercialize infigratinib for oncology and all other indications other than skeletal dysplasia indications in the U.S. and ...
Helensburgh Advertiser

Lomond School in Helensburgh joins QED Schools Group

Lomond School announced that it will be joining the newly launched QED Schools Group as both the first Scottish school and first International Baccalaureate (IB) school. The QED Schools Group aims to ...
Mena FN

QED Group And The Georgetown Strategy Group Launch Q2 Impact

ARLINGTON, Va., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Neelima Grover, Chief Executive Officer of QED Group LLC and President/Chief Executive Officer of QED Holdings, and Dave Harden, Managing Director of ...
Business Wire

BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQ™ (infigratinib) for Patients with Cholangiocarcinoma

PALO ALTO, Calif. & LUGANO, Switzerland--(BUSINESS WIRE)--BridgeBio Pharma, Inc. (Nasdaq: BBIO), through its affiliate QED Therapeutics, Inc., and Helsinn Group today announced that the US Food and ...